José Baselga, AstraZeneca cancer chief (Brent N. Clarke/FilmMagic via Getty Images)
Our 3rd annual UK biopharma event tops this week — on Zoom — with José Baselga, top biotech CEOs and a look at the global financial scene
The first few years of Pascal Soriot’s reign as CEO of AstraZeneca were tough to watch, at times. Setbacks were more common than breakthroughs, and its inability to finish its new headquarters building in Cambridge, UK, seemed emblematic of its inner confusion. True, Soriot had inherited the worst pipeline in Big Pharma, but investors fretted for some time when the company would get back on track.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters